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Mycobacterium tuberculosis is the etiological agent of tuberculosis (TB) and is the leading 16 
bacterial cause of mortality and morbidity in the world. One third of the world’s population is 17 
infected with TB, and in conjunction with HIV represents a serious problem that urgently needs 18 
addressing. TB is a disease of poverty and mostly affects young adults in their productive years, 19 
primarily in the developing world. The most recent report from the World Health Organisation 20 
states that 8 million new cases of TB were reported and that ~1.5 million people died from TB. 21 
The efficacy of treatment is threatened by the emergence of multi-drug and extensively-drug 22 
resistant strains of M. tuberculosis. It can be argued that, globally, M. tuberculosis is the single 23 
most important infectious agent affecting mankind. Our research aims to establish an academic-24 
industrial partnership with the goal of discovering new drug targets and hit-to-lead new 25 
chemical entities for TB drug discovery. 26 
 27 
Introduction  28 
In 2015 seventeen new Sustainable Development Goals (SDGs) were adopted by the United 29 
Nations [1]. Included amongst these goals was the ambitious aim to ‘end the epidemics of 30 
AIDS, tuberculosis, malaria and neglected tropical diseases’ [1].  Despite progress towards 31 
reaching this aim, the frequency of multi-drug resistant (MDR) and extensively-drug resistant 32 
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(XDR) forms of TB is rising and threatening to undermine global TB containment efforts as 1 
current treatment regimens lose their efficacy [2]. The continued high prevalence of TB can, at 2 
least in part, be attributed to problems with current anti-TB drugs. The nature of the treatment, 3 
which involves a combination of up to four drugs taken for a minimum of six months, and 4 
associated side-effects, often causes patients to discontinue therapy prematurely, leading to 5 
infection relapse and exacerbation of the problem of drug resistance, which is already 6 
beginning to emerge for the recently approved TB drugs, SirturoTM (TMC207) and DeltybaTM 7 
(Delamanid) [3,4]. Whilst poverty remains one of the main drivers of the TB pandemic, the 8 
development of new drugs remains a critical component of any plan to tackle TB. It is therefore 9 
vital that we replenish the drug pipeline with new targets and leads to establish more robust 10 
combination regimens for treating MDR/XDR-TB in order to ease the economic and health 11 
burden of this disease on Society (Figure 1).  12 
Many organisations, continue to employ a traditional target-based approach to antibiotic drug 13 
discovery, even in the knowledge that it is blighted by high attrition rates [5,6]. Applied to TB 14 
drug discovery, the problems of this approach are compounded by the limited number of 15 
validated targets. To address these challenges, we [7,reviewed in 8], and others [9-11], are 16 
increasingly turning to whole-cell screens to identify hits as well as new targets. Having 17 
demonstrated access to the target, hits are selected based upon their antibacterial activity and 18 
provide privileged starting points for target-focused medicinal chemistry programmes. 19 
However, one of the greatest challenges of scientific research is effectively transitioning good 20 
ideas and excellent science into translational outcomes. This process is rarely straightforward 21 
and often involves significant elements of serendipity. The history of drug discovery in general 22 
and antibiotic development in particular is littered with compounds for which ideal 23 
translational outcomes were not met. This high rate of attrition reflects the challenging 24 
landscape of drug discovery. Efforts to improve this hit rate have intensified, largely based on 25 
“smarter” screening strategies which take into account more parameters. This is illustrated by 26 
the high-throughput screening (HTS) campaigns of GSK’s compound repository (>2.5 million 27 
compounds) which produced what is now referred to as the TB box-set (177 compounds) [7]. 28 
A selection of these hits (MIC99 ~ 1 µM) were ranked according to their anti-TB activity, 29 
cytotoxicity and physico-chemical properties (e.g. cLogP, molecular weight, polar surface 30 
area). A second phenotypic HTS of GSK’s new 254,053 diversity set, the profile of which 31 
reflects the latest intelligence on how specific physico-chemical property descriptors (sp3 32 
character, lipophilicity/water solubility, molecular size) affect attrition at the various stages of 33 
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drug discovery after filtering by SMARTS and pIC50 data, provided 51 additional hits against 1 
M. tuberculosis with MIC99 < 10 µM, and expanded the TB box-set to 228 compounds. 2 
The process of improving a screen however still rests firmly on a strong foundation of basic 3 
biology. For example, the explosion in genomic sequencing has lead to unparalleled 4 
information about the molecular blue-print for all forms of life. The success of genomic 5 
annotation is informed by and depends upon on the availability of classical molecular and 6 
biochemical studies. The wealth of genomic sequencing would have a fraction of its usefulness 7 
if it were not for this basic functional information. It is possible that within the TB-Box-set 8 
may well be the next rifampicin or isoniazid, however without detailed knowledge of their 9 
mode of action, they remain un-useable. As a consequence, the success of phenotypic screening 10 
in (TB) drug discovery rests on there being efficient strategies for elucidating the cellular 11 
targets of identified hits. Fortunately, state-of-the-art genomic, proteomic and metabolomic 12 
tools are facilitating accelerated target identification, making whole-cell screens a viable (if not 13 
now preferred) alternative to the traditional methodologies that have been used to identify anti-14 
TB agents and, just as importantly, new targets. Nevertheless, this approach is not without its 15 
challenges: in many instances, target identification rests on the generation of spontaneous drug-16 
resistant mutants, with the expectation that resistance-conferring mutations, revealed by whole-17 
genome sequencing (WGS), identifies the protein target of a given hit. M. tuberculosis F0F1 18 
ATP synthase, for example, was identified in this way as the target for TMC207 [3]. However, 19 
resistance can occur through other mechanisms, which means that spontaneous drug-resistant 20 
mutations may not only arise in the drug target but also in other cellular proteins that interact 21 
with the inhibitor (e.g. InhA/KatG in the case of isoniazid [12,13]) or indeed the target. For 22 
these reasons, a strategy involving parallel orthogonal approaches must be used to ensure 23 
definitive and robust target identification. In this way, the development of new antimicrobials 24 
must be intimately tied to basic biology and the study of both the host and the pathogen. Three 25 
recent examples typify this relationship. 26 
 27 
It’s all in the details 28 
 29 
The nitro-benzothiazinone (BTZ) family of anti-tubercular compounds were first identified in 30 
2009 [14]. In that study, the BTZs were found to block the synthesis of the essential 31 
mycobacterial cell-wall polymer arabinan. A more precise mode of action was determined 32 
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through a combination of structure-activity studies, resistant mutant generation and 1 
transcriptomics, leading Makaraov and colleagues to identify DprE1 as the target of the BTZ 2 
compounds. This was a critical step in defining mode-of-action for these compounds, but was 3 
lacking molecular details. In 2012, two independent studies solved this problem by determining 4 
the first crystal structure of DprE1 in complex with BTZ [15,16]. The solved structures 5 
highlighted the critical moieties of the BTZ compound for DprE1 inhibition, information which 6 
is critical for lead-optimisation. Further studies demonstrated that the lethality of the BTZ 7 
compounds comes about not only through inhibition of DprE1 (and therefore blocking arabinan 8 
biosynthesis), but also as a result of a blockage in decaprenyl-phosphate recycling. This was 9 
demonstrated by the viability of a Corynebacterium glutamicum mutant lacking the enzyme 10 
acting upstream of DprE1, UbiA thereby also generating an arabinan-less mutant but one which 11 
does not generate decaprenyl-intermediates as a dead end [17]. The accumulation of 12 
decaprenyl-phosphoarabinose acts as a sink for this critical carrier molecule, which is in turn 13 
lethal. A detailed understanding of this relationship allows for a more nuanced view of how the 14 
pathway can be interfered with in order to kill these bacteria.  15 
 16 
A case of mistaken identity 17 
 18 
In 2013, the tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide (THPP) family of 19 
compounds were demonstrated to have remarkable anti-tubercular effects. This compound 20 
series was first described by Remuiñán et al in 2013 [18]. Using a combination of resistant 21 
mutant generation and lipid profiling a putative trehalose-monomycolate transporter named 22 
MmpL3, was concluded to be the likely target for these compounds. Surprisingly, MmpL3 had 23 
also been determined to be the likely target of several distinct classes of molecules including 24 
SQ109, adamantyl ureas, BM212, N-benzyl- 6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-25 
c]pyran] and indolcarboxamides [19-24]. By combining traditional biochemical and lipid 26 
profiling methods with cutting edge chemical proteomics and genetic screens, Cox and 27 
colleagues were able to show that the target of the THPPs is actually a crotonase-like protein 28 
called EchA6 and not MmpL3 [25]. This protein appears to play a role in a shunt pathway 29 
between the FAS-I and –II fatty acid synthesis pathways and so loss of EchA6 phenocopies the 30 
mycolate-lipid profile associated with MmpL3 depletion. The role of MmpL3 in this pathway 31 
is still somewhat murky. The simplest explanation is that it is moon-lighting as a drug importer, 32 
a feature which could have profound consequences in drug discovery. This re-assignment 33 
highlights the need for better MmpL3 functional assays and the importance of unbiased 34 
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approaches, such as chemical proteomics to determine mode-of-action for hit compounds. 1 
A new scaffold for a known target 2 
The biosynthesis of mycolic acids is one of the best developed targets for mycobacterial-3 
specific antibiotics. These cell-wall polymers form the outer membrane of the bacterium and 4 
are essential for their viability [26]. The key anti-mycobacterial drug isoniazid exerts its effect 5 
by blocking the enoyl-acyl carrier protein InhA [13]. A wealth of basic biochemistry and 6 
biology has gone into understanding the mechanism of this pro-drug and has primed the field 7 
for study of this pathway. A new family of indazole sulfonamides were found to possess anti-8 
tubercular activity against KasA [27]. KasA is a condensing enzyme in the FAS-II fatty acid 9 
synthesis pathway and is essential for viability in mycobacteria [28]. Past studies have 10 
identified KasA inhibitors, including thiolactomycin which inhibits a broad array of Kas-like 11 
enzymes [29]. Critical to the success of the key hit indazole sulfonamide is that it has excellent 12 
pharmacokinetic properties, allowing for in vivo studies supporting its development as an anti-13 
tubercular compound. While resistant-mutant generation suggested that KasA was indeed the 14 
target of this compound, prior experience with the THPPs highlighted the need for more robust 15 
target identification. In this case that included structural biology, chemical proteomics and in 16 
vitro biochemical assays. The co-crystal structure of KasA and hit molecule from the indazole 17 
sulfonamide series identified a distinct inhibition mechanism from existing inhibitors 18 
explaining the remarkable specificity of this series.  19 
Conclusion 20 
The field of mycobacterial drug discovery is littered with compounds that are either potent 21 
against target enzymes but have poor anti-bacterial power or have good anti-bacterial power 22 
but unknown mechanism(s). This high rate of attrition is made worse by the large number of 23 
compounds that prove to be cytotoxic or have otherwise poor pharmacokinetic properties. 24 
Central to this is the need for robust mode-of-action pipelines using a combination of traditional 25 
and modern tools. The three studies described above further highlight the absolute requirement 26 
of a strong basic science background in the field to enable drug discovery. This is where the 27 
interface between academic and industrial science is made very important. The open drug-28 
discovery initiative spear-headed by GSK is an excellent example of the promise of this type 29 
of collaboration. Through their efforts in identifying anti-mycobacterial compounds with good 30 
pharmacokinetic properties the wealth of knowledge about the tubercule baclli generated in 31 
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academia and elsewhere can be leveraged to develop new drugs aimed at tackling one of the 1 
biggest challenges in human-health today. 2 
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Figure 1. Separating good drugs from compound libraries. The rise of MDR- and XDR-TB has 3 
highlighted the poor options that populate first and second-line drug formulations. The identification of new 4 
drugs is a long and difficult process in which very few compounds make it successfully from screening libraries 5 
to useful medicines. Compounds are eliminated for a variety of reasons including poorly defined mode(s)-of-6 
action, poor pharmacokinetic-pharmacodynamic properties and toxicity among others. The identification of 7 
good hits in tuberculosis drug-discovery has significantly benefited from industry-academic collaborations. In 8 
particular, this has recently been enhanced through more robust mode-of-action studies and whole-cell 9 
phenotypic screening. 10 
